Cargando…

Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature review and structural analysis of drug resistance mechanisms

Background: Tenofovir (TFV) is a widely used treatment for chronic hepatitis B virus (HBV) infection. There is a high genetic barrier to the selection of TFV resistance-associated mutations (RAMs), but the distribution and clinical significance of TFV RAMs are not well understood. We here present as...

Descripción completa

Detalles Bibliográficos
Autores principales: Mokaya, Jolynne, McNaughton, Anna L., Bester, Phillip A, Goedhals, Dominique, Barnes, Eleanor, Marsden, Brian D, Matthews, Philippa C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033640/
https://www.ncbi.nlm.nih.gov/pubmed/33869791
http://dx.doi.org/10.12688/wellcomeopenres.15992.1
_version_ 1783676436724318208
author Mokaya, Jolynne
McNaughton, Anna L.
Bester, Phillip A
Goedhals, Dominique
Barnes, Eleanor
Marsden, Brian D
Matthews, Philippa C.
author_facet Mokaya, Jolynne
McNaughton, Anna L.
Bester, Phillip A
Goedhals, Dominique
Barnes, Eleanor
Marsden, Brian D
Matthews, Philippa C.
author_sort Mokaya, Jolynne
collection PubMed
description Background: Tenofovir (TFV) is a widely used treatment for chronic hepatitis B virus (HBV) infection. There is a high genetic barrier to the selection of TFV resistance-associated mutations (RAMs), but the distribution and clinical significance of TFV RAMs are not well understood. We here present assimilated evidence for putative TFV RAMs with the aims of cataloguing and characterising mutations that have been reported, and starting to develop insights into mechanisms of resistance. Methods: We carried out a systematic literature search in PubMed and Scopus to identify clinical, in vitro and in silico evidence of TFV resistance. We included peer-reviewed studies presenting original data regarding virological TFV breakthrough, using published methods to assess the quality of each study. We generated a list of RAMs that have been reported in association with TFV resistance, developing a ‘long-list’ (all reported RAMs) and a ‘short-list’ (a refined list supported by the most robust evidence). We assessed the potential functional and structural consequences by mapping onto the crystal structure for HIV reverse transcriptase (RT), as the structure of HBV RT has not been solved. Results: We identified a ‘long-list’ of 37 putative TFV RAMs in HBV RT, occurring within and outside sites of enzyme activity, some of which can be mapped onto a homologous HIV RT structure. A ‘short-list’ of nine sites are supported by the most robust evidence. If clinically significant resistance arises, it is most likely to be in the context of suites of multiple RAMs. Other factors including adherence, viral load, HBeAg status, HIV coinfection and NA dosage may also influence viraemic suppression. Conclusion: There is emerging evidence for polymorphisms that may reduce susceptibility to TVF. However, good correlation between viral sequence and treatment outcomes is currently lacking; further studies are essential to optimise individual treatment and public health approaches.
format Online
Article
Text
id pubmed-8033640
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-80336402021-04-15 Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature review and structural analysis of drug resistance mechanisms Mokaya, Jolynne McNaughton, Anna L. Bester, Phillip A Goedhals, Dominique Barnes, Eleanor Marsden, Brian D Matthews, Philippa C. Wellcome Open Res Systematic Review Background: Tenofovir (TFV) is a widely used treatment for chronic hepatitis B virus (HBV) infection. There is a high genetic barrier to the selection of TFV resistance-associated mutations (RAMs), but the distribution and clinical significance of TFV RAMs are not well understood. We here present assimilated evidence for putative TFV RAMs with the aims of cataloguing and characterising mutations that have been reported, and starting to develop insights into mechanisms of resistance. Methods: We carried out a systematic literature search in PubMed and Scopus to identify clinical, in vitro and in silico evidence of TFV resistance. We included peer-reviewed studies presenting original data regarding virological TFV breakthrough, using published methods to assess the quality of each study. We generated a list of RAMs that have been reported in association with TFV resistance, developing a ‘long-list’ (all reported RAMs) and a ‘short-list’ (a refined list supported by the most robust evidence). We assessed the potential functional and structural consequences by mapping onto the crystal structure for HIV reverse transcriptase (RT), as the structure of HBV RT has not been solved. Results: We identified a ‘long-list’ of 37 putative TFV RAMs in HBV RT, occurring within and outside sites of enzyme activity, some of which can be mapped onto a homologous HIV RT structure. A ‘short-list’ of nine sites are supported by the most robust evidence. If clinically significant resistance arises, it is most likely to be in the context of suites of multiple RAMs. Other factors including adherence, viral load, HBeAg status, HIV coinfection and NA dosage may also influence viraemic suppression. Conclusion: There is emerging evidence for polymorphisms that may reduce susceptibility to TVF. However, good correlation between viral sequence and treatment outcomes is currently lacking; further studies are essential to optimise individual treatment and public health approaches. F1000 Research Limited 2020-06-29 /pmc/articles/PMC8033640/ /pubmed/33869791 http://dx.doi.org/10.12688/wellcomeopenres.15992.1 Text en Copyright: © 2020 Mokaya J et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Systematic Review
Mokaya, Jolynne
McNaughton, Anna L.
Bester, Phillip A
Goedhals, Dominique
Barnes, Eleanor
Marsden, Brian D
Matthews, Philippa C.
Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature review and structural analysis of drug resistance mechanisms
title Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature review and structural analysis of drug resistance mechanisms
title_full Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature review and structural analysis of drug resistance mechanisms
title_fullStr Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature review and structural analysis of drug resistance mechanisms
title_full_unstemmed Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature review and structural analysis of drug resistance mechanisms
title_short Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature review and structural analysis of drug resistance mechanisms
title_sort hepatitis b virus resistance to tenofovir: fact or fiction? a systematic literature review and structural analysis of drug resistance mechanisms
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033640/
https://www.ncbi.nlm.nih.gov/pubmed/33869791
http://dx.doi.org/10.12688/wellcomeopenres.15992.1
work_keys_str_mv AT mokayajolynne hepatitisbvirusresistancetotenofovirfactorfictionasystematicliteraturereviewandstructuralanalysisofdrugresistancemechanisms
AT mcnaughtonannal hepatitisbvirusresistancetotenofovirfactorfictionasystematicliteraturereviewandstructuralanalysisofdrugresistancemechanisms
AT besterphillipa hepatitisbvirusresistancetotenofovirfactorfictionasystematicliteraturereviewandstructuralanalysisofdrugresistancemechanisms
AT goedhalsdominique hepatitisbvirusresistancetotenofovirfactorfictionasystematicliteraturereviewandstructuralanalysisofdrugresistancemechanisms
AT barneseleanor hepatitisbvirusresistancetotenofovirfactorfictionasystematicliteraturereviewandstructuralanalysisofdrugresistancemechanisms
AT marsdenbriand hepatitisbvirusresistancetotenofovirfactorfictionasystematicliteraturereviewandstructuralanalysisofdrugresistancemechanisms
AT matthewsphilippac hepatitisbvirusresistancetotenofovirfactorfictionasystematicliteraturereviewandstructuralanalysisofdrugresistancemechanisms